] . Temporal and external validation of the fullPIERS model for the prediction of adverse maternal outcomes in women with pre-eclampsia. Pregnancy Hypertens. 2019;15:42-50. 
(887.01 KB)
(887.01 KB). Assessment of the fullPIERS Risk Prediction Model in Women With Early-Onset Preeclampsia. Hypertension. 2018;71(4):659-665. (237.99 KB)
(237.99 KB). Early diagnosis of preeclampsia using placental growth factor: An operational pilot study in Maputo, Mozambique. Pregnancy Hypertens. 2018;11:26-31. (374.54 KB)
(374.54 KB). Diagnostic Performance of Placental Growth Factor in Women With Suspected Preeclampsia Attending Antenatal Facilities in Maputo, Mozambique. Hypertension. 2017;69(3):469-474. (378.99 KB)
(378.99 KB). External Validation of the fullPIERS Model for Predicting Adverse Maternal Outcomes in Pregnancy Hypertension in Low- and Middle-Income Countries. Hypertension. 2017;69(4):705-711. (149.83 KB)
(149.83 KB). Placental Growth Factor as a Prognostic Tool in Women With Hypertensive Disorders of Pregnancy: A Systematic Review. Hypertension. 2017;70(6):1228-1237. (986.49 KB)
(986.49 KB). Reverse innovation in maternal health. Obstet Med. 2017;10(3):113-119. (710.03 KB)
(710.03 KB). Seasonal variation in geographical access to maternal health services in regions of southern Mozambique. Int J Health Geogr. 2017;16(1):1. (9.27 MB)
(9.27 MB). Community perspectives on the determinants of maternal health in rural southern Mozambique: a qualitative study. Reprod Health. 2016;13(Suppl 2):112. (1019.85 KB)
(1019.85 KB). Assessing the incremental value of blood oxygen saturation (SpO(2)) in the miniPIERS (Pre-eclampsia Integrated Estimate of RiSk) Risk Prediction Model. J Obstet Gynaecol Can. 2015;37(1):16-24. (1.11 MB)
(1.11 MB). Development and internal validation of a multivariable model to predict perinatal death in pregnancy hypertension. Pregnancy Hypertens. 2015;5(4):315-21. (505.41 KB)
(505.41 KB). Usability and Feasibility of PIERS on the Move: An mHealth App for Pre-Eclampsia Triage. JMIR Mhealth Uhealth. 2015;3(2):e37. (831.85 KB)
(831.85 KB). Development of mHealth applications for pre-eclampsia triage. IEEE J Biomed Health Inform. 2014;18(6):1857-64. (300.31 KB)
(300.31 KB). Predicting complications in pre-eclampsia: external validation of the fullPIERS model using the PETRA trial dataset. Eur J Obstet Gynecol Reprod Biol. 2014;179:58-62. (317.15 KB)
(317.15 KB). A risk prediction model for the assessment and triage of women with hypertensive disorders of pregnancy in low-resourced settings: the miniPIERS (Pre-eclampsia Integrated Estimate of RiSk) multi-country prospective cohort study. PLoS Med. 2014;11(1):e1001589. (353.97 KB)
(353.97 KB). Uric Acid as a predictor of adverse maternal and perinatal outcomes in women hospitalized with preeclampsia. J Obstet Gynaecol Can. 2014;36(10):870-877. (1021.64 KB)
(1021.64 KB). An assessment of predictive value of the biophysical profile in women with preeclampsia using data from the fullPIERS database. Pregnancy Hypertens. 2013;3(3):166-71. (232.97 KB)
(232.97 KB). Performance of the fullPIERS model in predicting adverse maternal outcomes in pre-eclampsia using patient data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) cohort, collected on admission. BJOG. 2013;120(1):113-8. (85.31 KB)
(85.31 KB). Random urine albumin:creatinine ratio in high-risk pregnancy - Is it clinically useful?. Pregnancy Hypertens. 2013;3(2):112-4. (189.28 KB)
(189.28 KB). The PIERS experience: research or quality improvement?. J Obstet Gynaecol Can. 2012;34(4):379-81. (233.18 KB)
(233.18 KB). Abnormal liver function tests as predictors of adverse maternal outcomes in women with preeclampsia. J Obstet Gynaecol Can. 2011;33(10):995-1004. (280.12 KB)
(280.12 KB). Assessment, surveillance and prognosis in pre-eclampsia. Best Pract Res Clin Obstet Gynaecol. 2011;25(4):449-62. (178.71 KB)
(178.71 KB). Oxygen saturation as a predictor of adverse maternal outcomes in women with preeclampsia. J Obstet Gynaecol Can. 2011;33(7):705-714. (383.37 KB)
(383.37 KB). PIERS proteinuria: relationship with adverse maternal and perinatal outcome. J Obstet Gynaecol Can. 2011;33(6):588-597. (292.91 KB)
(292.91 KB). Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet. 2011;377(9761):219-27. (201.46 KB)
(201.46 KB). The role of platelet counts in the assessment of inpatient women with preeclampsia. J Obstet Gynaecol Can. 2011;33(9):900-8. (370.8 KB)
(370.8 KB). Using clinical symptoms to predict adverse maternal and perinatal outcomes in women with preeclampsia: data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) study. J Obstet Gynaecol Can. 2011;33(8):803-809. (269.78 KB)
(269.78 KB). Pre-eclampsia. Lancet. 2010;376(9741):631-44. (809.94 KB)
(809.94 KB)